Through ongoing collaboration, new companion diagnostic aims to deliver next-generation sequencing results in as little as 24 hours to help advance precision oncology.
Posts
Seagen and LAVA Therapeutics inked a licensing deal for LAVA’s Gammabody platform for solid tumors, which can potentially exceed $700 million.
